BioCentury
ARTICLE | Clinical News

ASB17061: Phase II started

February 11, 2013 8:00 AM UTC

In its fiscal 3Q12 earnings ending Dec. 31, 2012, Daiichi said it began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate 3 dose levels of oral ASB17061 once daily for 28 days in abo...